Research programme: radiopharmaceutical theranostics - Aktis Oncology
Alternative Names: Radiopharmaceutical theranosticsLatest Information Update: 23 Jul 2021
At a glance
- Originator Aktis Oncology
- Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours